



Express Mail No: EL 501 759 414 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Soff et al.

Confirmation No.: 2549

Serial No.: 09/500,397

Group Art Unit: 1642

Filed: February 8, 2000

Examiner: Minh-Tam B. Davis

For: **METHODS AND COMPOSITIONS  
FOR GENERATING ANGIOSTATIN**

Attorney Docket No.: 10561-005-999

**REPLY UNDER 37 C.F.R. 1.116**

Box AF  
Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

In response to a Final Office Action mailed October 21, 2002 and in accordance with Rule 116 of the Rules of the Practice, please consider the amendments and remarks below intended to put the claims into condition for allowance. Applicants submit herewith: (1) Exhibit A, a copy of the claims that will be pending upon entry of the instant amendment; (2) Exhibit B, copies of several Declarations submitted in parent Application No. 08/991,761; (3) an Amendment Fee Transmittal Sheet (in duplicate), accompanied by the appropriate provision authorizing payment of the required fee; (4) a Petition for Extension of Time (in duplicate), accompanied by the appropriate provision authorizing payment of the required fee; and (5) a Notice of Appeal (in duplicate), accompanied by the appropriate provision authorizing payment of the required fee.

It is estimated that no other fee is required for filing this Reply. However, should the United States Patent and Trademark Office determine otherwise, please charge any additional fee to Pennie & Edmonds LLP Deposit Account No. 16-1150.

**IN THE CLAIMS:**

Please add the following new claims:

89. (new) The method of claim 19 wherein the angiogenic disease is selected from the group consisting of neoplastic diseases including tumors and tumor metastasis; benign tumors including hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyrogenic granulomas; connective tissue disorders including rheumatoid arthritis and atherosclerosis; ocular angiogenic diseases including diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental

#  
211D NE  
KO  
424-03

RECEIVED  
APR 23 2003  
TECH CENTER 1600/2900

Plaint  
T.M.  
08/10/03



Express Mail No. EL 501 759 414 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Soff et al.

Confirmation No.: 2549

Serial No.: 09/500,397

Art Unit: 1642

Filed: February 8, 2000

Examiner: Minh-Tam B. Davis

For: METHODS AND COMPOSITIONS  
FOR GENERATING  
ANGIOSTATIN

Attorney Docket No: 10561-005-999

FEE TRANSMITTAL SHEET

Box AF  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

The fee required to be filed with the accompanying amendment of even date herewith concerning the above-identified application has been estimated to be \$0.00.

The claim amendment fee has been estimated as shown below:

(Col. 1)0		(Col. 2)		(Col. 3)		<input type="checkbox"/> SMALL ENTITY		<input checked="" type="checkbox"/> OTHER THAN A SMALL ENTITY	
CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID		PRESENT EXTRA		RATE		ADDIT. FEE	
TOTAL	20	MINUS	62	0	x 9	\$		x 18	\$ 0.00
INDEP.	2	MINUS	9	0	x 42	\$		x 84	\$ 0.00
						\$		\$	0.00
<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEP. CLAIM						TOTAL	\$	OR	TOTAL \$ 0.00

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150.  
A copy of this sheet is enclosed.

Respectfully submitted,

Date: April 17, 2003

*Laura A. Coruzzi*  
Laura A. Coruzzi 30,742  
(Reg. No.)  
PENNIE & EDMONDS LLP  
1155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090

Enclosure